Health Technology Assessment (HTA) for Orphan Drugs in Cost-Effectiveness (CE) Markets- Current Development and Future Trends
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1464
https://www.valueinhealthjournal.com/article/S1098-3015(16)32830-3/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1381
First Page :
A601
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32830-3&doi=10.1016/j.jval.2016.09.1464